Novel approach could help foil tough cystic fibrosis infectionsApril 25th, 2009 - 1:54 pm ICT by ANI
Washington, Apr 25 (ANI): Researchers from Dartmouth Medical School have come up with a novel approach for inhibiting relentless bacterial infections that thrive in the lungs of people with cystic fibrosis (CF).
The researchers have found that combining a mainstay antibiotic with certain drugs to deprive the bacteria of iron, which facilitates their persistent growth, appears to boost infection killing.
Cystic fibrosis patients are plagued by infections of the bacteria Pseudomonas aeruginosa. Their mucous-clogged lungs are fertile incubators for the bacteria to breed and cluster in slimy communities called biofilms that become increasingly drug resistant and damaging.
Tobramycin, the antibiotic routinely used against the microbes, can control, but not efficiently eliminate Pseudomonas established on CF airway cells.
For the study, the team used two agents already approved by the Federal Drug Administration to treat acute iron poisoning or overload that can enhance the ability of tobramycin against Pseudomonas infection.
“The beauty is that we are mixing FDA-approved drugs– antibiotics and iron chelators– to potentiate the effect of tobramycin on biofilm formation,” said lead author Dr. Sophie Moreau-Marquis, a research associate.
“It’s an exciting translational framework that opens the door to potentially treating CF patients, taking the novel model we developed from the lab hopefully to the clinic,” she added.
The team used two FDA-approved iron chelators, deferoxamine and deferasirox, that can remove excess iron from the system by binding to the metal in a process called chelation.
To mimic the clinical environment, they stuck to the maximum possible tobramycin dose of 1,000 micrograms per milliliter, mixed with a chelator.
The researchers found that the combination had a dramatic effect. It disrupted the mass of established and highly resistant bacteria in human airway cells by 90 percent and it also prevented formation of damaging biofilms.
In contrast, neither an iron chelator nor tobramycin alone had such success.
The study appears in the American Journal of Respiratory Cell and Molecular Biology. (ANI)
- Novel drug may benefit cystic fibrosis patients - Dec 18, 2010
- Nutrition-starved bugs become resistant to antibiotics - Nov 18, 2011
- How bacteria resist attack - Nov 02, 2009
- New discovery may help treatment of multi-drug resistant infections - Jan 06, 2011
- Drug targets defective protein that causes cystic fibrosis - Nov 18, 2010
- Combination therapy shows promise in treating devastating cystic fibrosis - Apr 25, 2011
- New discovery may help treat chronic infections - Dec 20, 2009
- New method to fight bacterial infections linked to contact lenses - Jan 26, 2011
- Boffins come closer to understanding how cystic fibrosis causes lung disease - Apr 29, 2010
- Eat candies to ward off rare, but deadly infections - Jan 05, 2010
- Protein involved in cystic fibrosis linked to chronic lung diseases - Dec 30, 2010
- Human lungs can sweep out intruders - Aug 26, 2012
- Infliximab treatment effective for cystic fibrosis and Crohn's disease - Apr 20, 2010
- Soon, cold plasma jets to replace antibiotics - Dec 16, 2010
- Crosstalk between ion channels leads to new therapeutic strategy - Sep 20, 2010
Tags: biofilms, cf patients, chelator, clinical environment, cystic fibrosis, cystic fibrosis patients, dartmouth medical school, deferoxamine, dramatic effect, excess iron, fda approved drugs, federal drug administration, iron chelators, iron poisoning, milliliter, novel approach, novel model, pseudomonas infection, resistant bacteria, sophie moreau